Daclatasvir: potential role in hepatitis C [Corrigendum]
Drug Design, Development and Therapy, 2014 Lee C. Drug Des Devel Ther. 2013;7:1223–1233. On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor,
Lee C
doaj
Hepatic Medicine: Evidence and Research, 2016 Stanislas Pol, Marion Corouge, Anaïs Vallet-Pichard Université Paris Descartes, Liver Department, Assistance Publique Hôpitaux de Paris, Cochin Hospital, French Institute of Health and Medical Research UMS20, Institut Pasteur, Paris ...
Pol S, Corouge M, Vallet-Pichard A
doaj
Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus. [PDF]
Antiviral Res, 2018 Zhou S +10 more
europepmc +1 more source
Identification of Bioactive Compound From Microalga BTM 11 as Hepatitis C Virus RNA Helicase Inhibitor [PDF]
, 2015 Hepatitis C virus (HCV) is the major causative agent of chronic liver disease. Recently, the inhibition of NS3 RNA helicase/ATPase activity is being explored as the specifically targeted antiviral therapy (STAT) against HCV infection.
Farida, H. (Hilda) +4 more
core
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015 The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver ...
M. V. Mayevskaya +2 more
doaj
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. [PDF]
Antimicrob Agents Chemother, 2017 Ng TI +14 more
europepmc +1 more source
Molecular mechanism of highly potent NS5A inhibitors [PDF]
Hepatitis C is responsible for causing chronic infections in over 170 million people all over the world who are at a risk of developing into liver cirrhosis and hepatocellular carcinoma, locating HCV in a major public health burden. Until recently, the standard-of care treatment consisted of Interferon-alpha and ribavirin, in addition to non-structural
openaire
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. [PDF]
Antimicrob Agents Chemother, 2016 Owens CM +19 more
europepmc +1 more source
Hepatitis C Virus Nonstructural 5A Protein Inhibits Lipopolysaccharide-Mediated Apoptosis of Hepatocytes by Decreasing Expression of Toll-Like Receptor 4 [PDF]
, 2017 Background. Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) has been shown to modulate multiple cellular processes, including apoptosis. The aim of this study was to assess the effects of HCV NS5A on apoptosis induced by Toll-like receptor (TLR ...
Arai, Makoto +12 more
core
Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor. [PDF]
Antimicrob Agents Chemother, 2016 Owens CM +9 more
europepmc +1 more source